CL2017000670A1 - Método y composición para producir agentes regenerativos anti-inflamatorios/anti-catabólicos mejorados a partir de fluido fisiológico autólogo - Google Patents
Método y composición para producir agentes regenerativos anti-inflamatorios/anti-catabólicos mejorados a partir de fluido fisiológico autólogoInfo
- Publication number
- CL2017000670A1 CL2017000670A1 CL2017000670A CL2017000670A CL2017000670A1 CL 2017000670 A1 CL2017000670 A1 CL 2017000670A1 CL 2017000670 A CL2017000670 A CL 2017000670A CL 2017000670 A CL2017000670 A CL 2017000670A CL 2017000670 A1 CL2017000670 A1 CL 2017000670A1
- Authority
- CL
- Chile
- Prior art keywords
- chronic
- blood
- component
- inflammatory
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 230000003160 anti-catabolic effect Effects 0.000 title abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 3
- 230000001172 regenerating effect Effects 0.000 title abstract 2
- 239000012530 fluid Substances 0.000 title 1
- 230000001684 chronic effect Effects 0.000 abstract 12
- 239000008280 blood Substances 0.000 abstract 9
- 210000004369 blood Anatomy 0.000 abstract 9
- 208000000491 Tendinopathy Diseases 0.000 abstract 4
- 208000023835 Tendon disease Diseases 0.000 abstract 4
- 230000003412 degenerative effect Effects 0.000 abstract 4
- 208000013515 tendinosis Diseases 0.000 abstract 4
- 238000011282 treatment Methods 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000004744 fabric Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 230000003387 muscular Effects 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
Abstract
<p>SE DESCRIBEN MÉTODOS DE PRODUCCIÓN DE UNA COMPOSICIÓN AUTÓLOGA ÚTIL PARA EL TRATAMIENTO DE TEJIDOS CONECTIVOS DAÑADOS Y/O LESIONADOS, TENDINOSIS CRÓNICA, DESGARRES MUSCULARES CRÓNICOS Y/O CONDICIONES DEGENERATIVAS CRÓNICAS DE LAS ARTICULACIONES Y TRASTORNOS INFLAMATORIOS DE LA PIEL EN UN MAMÍFERO; EL MÉTODO COMPRENDE PREPARAR UN COMPONENTE ANTI-INFLAMATORIO/ANTI-CATABÓLICO DE LA COMPOSICIÓN AUTÓLOGA QUE COMPRENDE IL-1RA Y TIMPS; SE PREPARA UN COMPONENTE ANTI-INFLAMATORIO/ANTI-CATABÓLICO QUE COMPRENDE: COLECTAR SANGRE DEL MAMÍFERO; SUMINISTRAR LA SANGRE A UN TUBA; INCUBAR LA SANGRE A UNA TEMPERATURA DE APROXIMADAMENTE 37°C A APROXIMADAMENTE 39°C POR APROXIMADAMENTE 24 HORAS, DE PREFERENCIA EN PRESENCIA DE CITRATO DE SODIO; CENTRIFUGAR IA SANGRE PARA SEPARAR LA SANGRE EN UN COMPONENTE DE SOBRENADANTE Y UNA FRACCIÓN CELULAR; Y COLECTAR EL COMPONENTE DE SOBRENADANTE; EL MÉTODO COMPRENDE ADEMÁS EL PASO DE PREPARAR UN COMPONENTE REGENERATIVO DE LA COMPOSICIÓN ANTÓLOGA QUE COMPRENDE: COLECTAR SANGRE DEL MAMÍFERO; SUMINISTRAR LA SANGRE A UN TUBA EN PRESENCIA DE ÁCIDO CÍTRICO A APROXIMADAMENTE 4%; CENTRIFUGAR LA SANGRE PARA SEPARAR UN COMPONENTE DE PLASMA RICO EN PLAQUETAS DE LA SANGRE ENTERA; COLECTAR EL COMPONENTE DE PLASMA RICO EN PLAQUETAS; Y MEZCLAR EL COMPONENTE DE SOBRENADANTE CON EL COMPONENTE DE PLASMA RICO EN PLAQUETAS PARA PROVEER LA COMPOSICIÓN ANTÓLOGA; SE PROVEE TAMBIÉN UN MÉTODO DE TRATAMIENTO DE TEJIDOS CONECTIVOS DAÑADOS Y/O LESIONADOS, TENDINOSIS CRÓNICA, DESGARRES MUSCULARES CRÓNICOS Y/O CONDICIONES DEGENERATIVAS CRÓNICAS DE LAS ARTICULACIONES Y TRASTORNOS INFLAMATORIOS DE LA PIEL EN UN SUJETO CON LA COMPOSICIÓN AUTÓLOGA, Y UNA COMPOSICIÓN AUTÓLOGA PARA EL TRATAMIENTO DE TEJIDOS CONECTIVOS DAÑADOS Y/O LESIONADOS, TENDINOSIS CRÓNICA, DESGARRES MUSCULARES CRÓNICOS Y/O CONDICIONES DEGENERATIVAS CRÓNICAS DE LAS ARTICULACIONES Y TRASTORNOS INFLAMATORIOS DE LA PIEL EN UN MAMÍFERO, Y EL USO DE LA COMPOSICIÓN AUTÓLOGA PARA EL TRATAMIENTO DE TEJIDOS CONECTIVOS DAÑADOS Y/O LESIONADOS, TENDINOSIS CRÓNICA, DESGARRES MUSCULARES CRÓNICOS Y/O CONDICIONES DEGENERATIVAS CRÓNICAS DE LAS ARTICULACIONES Y TRASTORNOS INFLAMATORIOS DE LA PIEL EN UN MAMÍFERO.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2866480A CA2866480A1 (en) | 2014-09-30 | 2014-09-30 | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
| CA2891445A CA2891445A1 (en) | 2014-09-30 | 2015-05-14 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
| CA2900537A CA2900537A1 (en) | 2014-09-30 | 2015-08-13 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000670A1 true CL2017000670A1 (es) | 2017-11-10 |
Family
ID=55590205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000670A CL2017000670A1 (es) | 2014-09-30 | 2017-03-20 | Método y composición para producir agentes regenerativos anti-inflamatorios/anti-catabólicos mejorados a partir de fluido fisiológico autólogo |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10532072B2 (es) |
| EP (1) | EP3200817B1 (es) |
| JP (1) | JP6646660B2 (es) |
| KR (1) | KR102455394B1 (es) |
| CN (1) | CN107073083B (es) |
| AU (1) | AU2015327723B2 (es) |
| BR (1) | BR112017006410A2 (es) |
| CA (4) | CA2866480A1 (es) |
| CL (1) | CL2017000670A1 (es) |
| ES (1) | ES2912773T3 (es) |
| GB (1) | GB2546224B (es) |
| IL (1) | IL251082B (es) |
| LT (1) | LT3200817T (es) |
| MX (1) | MX2017004131A (es) |
| RU (1) | RU2708242C2 (es) |
| WO (1) | WO2016049746A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2866480A1 (en) | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
| CA2950659A1 (en) * | 2016-12-06 | 2018-06-06 | Antnor Limited | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
| EP3613424A1 (en) * | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
| WO2020243807A1 (en) * | 2019-06-05 | 2020-12-10 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
| RU2747589C1 (ru) * | 2019-12-09 | 2021-05-11 | Руслан Яверович Атлуханов | Способ лечения повреждения мениска коленного сустава |
| CA3076046A1 (en) * | 2020-03-17 | 2021-09-17 | Antnor Limited | Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid with shortened incubation time |
| CA3106197A1 (en) * | 2021-01-20 | 2022-07-20 | Antnor Limited | Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines |
| JP7025070B1 (ja) * | 2021-05-14 | 2022-02-24 | セルソース株式会社 | 血液由来成長因子含有組成物及びその調製方法 |
| JP7175055B1 (ja) * | 2021-05-14 | 2022-11-18 | セルソース株式会社 | 血液由来成長因子含有組成物及びその調製方法 |
| CN114146096B (zh) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | 一种富含细胞因子的条件血清的制备方法及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09509681A (ja) | 1994-12-16 | 1997-09-30 | バクスター、インターナショナル、インコーポレイテッド | 供血者血液特性の制御 |
| DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
| US20030166069A1 (en) | 2000-11-28 | 2003-09-04 | Amgen, Inc. | Interleukin-1 receptor antagonist-like molecules and uses thereof |
| US20060177515A1 (en) | 2005-02-09 | 2006-08-10 | Reinhold Schmieding | Method of producing autogenous or allogenic blood serum and related logistics |
| GB0700940D0 (en) | 2007-01-18 | 2007-02-28 | Univ Newcastle | Reverse shoulder prosthesis |
| EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
| US8460227B2 (en) * | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
| CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| KR101313755B1 (ko) | 2010-12-09 | 2013-10-01 | 이선민 | 상피조직 또는 피하조직 재생용 자가혈장의 제조방법 및 이를 함유하는 조성물 |
| WO2013114359A1 (en) | 2012-01-31 | 2013-08-08 | Estar Technologies Ltd | System and method for producing interleukin receptor antagonist (ira) |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| CA2866480A1 (en) | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
-
2014
- 2014-09-30 CA CA2866480A patent/CA2866480A1/en not_active Abandoned
-
2015
- 2015-05-14 CA CA2891445A patent/CA2891445A1/en not_active Abandoned
- 2015-08-13 CA CA2900537A patent/CA2900537A1/en not_active Abandoned
- 2015-09-30 KR KR1020177011345A patent/KR102455394B1/ko active IP Right Grant
- 2015-09-30 JP JP2017518238A patent/JP6646660B2/ja active Active
- 2015-09-30 US US15/515,996 patent/US10532072B2/en active Active
- 2015-09-30 RU RU2017114523A patent/RU2708242C2/ru active
- 2015-09-30 AU AU2015327723A patent/AU2015327723B2/en active Active
- 2015-09-30 MX MX2017004131A patent/MX2017004131A/es unknown
- 2015-09-30 CA CA2962289A patent/CA2962289C/en active Active
- 2015-09-30 CN CN201580053264.6A patent/CN107073083B/zh active Active
- 2015-09-30 WO PCT/CA2015/000521 patent/WO2016049746A1/en active Application Filing
- 2015-09-30 LT LTEPPCT/CA2015/000521T patent/LT3200817T/lt unknown
- 2015-09-30 BR BR112017006410A patent/BR112017006410A2/pt active Search and Examination
- 2015-09-30 ES ES15847588T patent/ES2912773T3/es active Active
- 2015-09-30 EP EP15847588.9A patent/EP3200817B1/en active Active
- 2015-09-30 GB GB1706803.2A patent/GB2546224B/en active Active
-
2017
- 2017-03-09 IL IL251082A patent/IL251082B/en active IP Right Grant
- 2017-03-20 CL CL2017000670A patent/CL2017000670A1/es unknown
-
2020
- 2020-01-13 US US16/741,627 patent/US12023352B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016049746A1 (en) | 2016-04-07 |
| RU2017114523A3 (es) | 2019-05-06 |
| JP6646660B2 (ja) | 2020-02-14 |
| AU2015327723B2 (en) | 2020-10-22 |
| IL251082A0 (en) | 2017-04-30 |
| US20200163991A1 (en) | 2020-05-28 |
| RU2708242C2 (ru) | 2019-12-05 |
| CA2891445A1 (en) | 2016-03-30 |
| US10532072B2 (en) | 2020-01-14 |
| ES2912773T3 (es) | 2022-05-27 |
| CA2962289C (en) | 2021-01-19 |
| EP3200817A1 (en) | 2017-08-09 |
| CN107073083A (zh) | 2017-08-18 |
| CA2866480A1 (en) | 2016-03-30 |
| CA2900537A1 (en) | 2016-03-30 |
| KR20170063836A (ko) | 2017-06-08 |
| AU2015327723A1 (en) | 2017-04-13 |
| GB2546224B (en) | 2020-04-22 |
| CA2962289A1 (en) | 2016-04-07 |
| IL251082B (en) | 2020-03-31 |
| EP3200817A4 (en) | 2018-06-20 |
| GB2546224A (en) | 2017-07-12 |
| EP3200817B1 (en) | 2022-03-02 |
| MX2017004131A (es) | 2017-06-19 |
| LT3200817T (lt) | 2022-08-10 |
| RU2017114523A (ru) | 2018-11-07 |
| US20170296583A1 (en) | 2017-10-19 |
| GB201706803D0 (en) | 2017-06-14 |
| KR102455394B1 (ko) | 2022-10-17 |
| US12023352B2 (en) | 2024-07-02 |
| CN107073083B (zh) | 2021-07-06 |
| BR112017006410A2 (pt) | 2017-12-19 |
| JP2017533896A (ja) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000670A1 (es) | Método y composición para producir agentes regenerativos anti-inflamatorios/anti-catabólicos mejorados a partir de fluido fisiológico autólogo | |
| CL2021000972A1 (es) | Inhibidores de la proteína tirosina fosfatasa | |
| BR112015021888A2 (pt) | inibidores de dna-ik | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| CL2017003218A1 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| SV2011003828A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| BR112018075073A2 (pt) | composições nasais de canabidiol | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112014018524A8 (pt) | Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras | |
| FR3037958B1 (fr) | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| MX2014014840A (es) | Peptido - mimeticos de la horquilla beta. | |
| MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| WO2015112793A3 (en) | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof | |
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| EA201692292A1 (ru) | Соединения и композиции для стимулирования хондрогенеза | |
| BR112017012588A2 (pt) | compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta) | |
| BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina | |
| BR112018072741A2 (pt) | método para a profilaxia de infecção pelo vírus da zika | |
| UY37087A (es) | Moléculas con utilidad pesticida, y los productos intermedios, composiciones, y procesos relacionados con ellas | |
| CL2008002414A1 (es) | Compuestos derivados de tetrahidronaftalenos sustituidos, composicion farmaceutica que comprende dichos compuestos, proceso de preparacion de dicha composicion y uso de los compuestos para tratar y/o prevenir trastornos del metabolismo de acidos grasos y trastornos de la utilizacion de la glucosa. |